Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 3
2(40.0%)
Phase 1
1(20.0%)
5Total
Phase 2(2)
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06202027Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

Role: lead

NCT03433560Completed

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)

Role: lead

NCT02094417Phase 2Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia

Role: lead

NCT02982005Phase 3Completed

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Role: lead

NCT06206135Recruiting

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

Role: lead

NCT06186934Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Role: lead

NCT01898156Phase 1Terminated

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Role: lead

NCT03822507Phase 3Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Role: collaborator

NCT04289207Phase 2Unknown

Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

Role: collaborator

All 9 trials loaded